激活的 Akt/PKB 在癌症中的预后意义-猫眼课题宝

激活的 Akt/PKB 在癌症中的预后意义

批准号：

7251492

负责人：

ODILE DAVID

金额：

$12.02万

依托单位：

UNIVERSITY OF ILLINOIS AT CHICAGO

依托单位国家：

美国

项目类别：

财政年份：

2005

资助国家：

美国

项目状态：

已结题

起止时间：

2005-08-01 至 2010-05-31

来源：

https://reporter.nih.gov/project-details/7251492

关键词：

Address Apoptosis Apoptotic Behavior Bronchoscopy Cancer Patient Cancer cell line Cell Survival Characteristics Cisplatin/Gemcitabine/Paclitaxel Clinical Clinical Data Clinical Investigator Clinical Research Data Diagnosis Diagnostic End Point Epidermal Growth Factor Receptor Event Experimental Models Flow Cytometry Gefitinib Histologic Human Immunohistochemistry Individual Investigation Knowledge Laboratories Malignant - descriptor Malignant Neoplasms Malignant neoplasm of lung Mentors Messenger RNA Methods Molecular Molecular Target Newly Diagnosed Non-Malignant Non-Small-Cell Lung Carcinoma Outcome PTEN gene Patients Phosphorylation Population Predictive Value Protein Overexpression Proteins Proto-Oncogene Proteins c-akt Range Recruitment Activity Role Signal Transduction Small Cell Carcinoma Small Interfering RNA Specimen Subgroup Testing Therapeutic Tissues Training Tumor Suppressor Proteins Western Blotting base cancer cell carcinogenesis career chemotherapeutic agent chemotherapy cohort follow-up multidisciplinary neoplastic cell novel therapeutics patient oriented research prognostic programs response therapeutic target tumor

项目摘要

项目成果

ODILE DAVID的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

This K23 application proposes a carefully planned program of mentored patient-oriented research and concurrent multidisciplinary didactic training in the methods of clinical and laboratory investigation. The candidate plans a career as an independent clinical investigator focusing on patient-oriented research related to molecular determinants of chemoresistance and prognostic outcome. The Tulane/LSU General Clinical Research Center, including the GCRC Core Laboratory, will serve as the primary

期刊论文(0)

专著(0)

科研奖励(0)

会议论文